Following the Huggins development of the first systemic treatment for metastatic cancer, androgen deprivation has been central in the management of metastatic hormone-sensitive prostate cancer (mHSPC).
However, we recently realised that it is not so simple. What is metastatic disease and how do new imaging modalities challenge our understanding of it? What is the role of local treatment? Does oligometastatic disease exist and if so, should we treat it differently? Combination therapy is associated with clinically significant improvements in survival. What combined therapies should we use and on which patients? If combination therapy has excellent feedback, why do only a few patients receive it?
These are some of the questions that we will address in this UROwebinar as we separate the facts from the beliefs with regard to mHSPC. Esteemed experts of the EAU Section of Oncological Urology (ESOU) will share vital research and their valuable insights with you in detail.
P. Cornford, Liverpool (GB)
M. De Santis, Berlin (DE)
N. Mottet, Saint-Étienne (FR)
- Publication date: January 2021
- Available languages: English
- Topic: Prostate cancer
- CME: 1 European CME credits (ECMEC)
- Duration: Approx. 60 – 90 minutes